Aging is the process in which animals, human beings and plants, which have ceased growing, become older. In human beings particularly, aging is considered as a risk factor as it increases susceptibility to get diseases and even death. The causes of aging are not well known but there are numerous theories that discuss this. Most of the theories relate aging to the damage concept. This explains that continuous accumulation of damage causes body systems to fail or slow down. This journal, by editor in chief Mikhail Blagosklonny is ranked third in documents that discuss aging. In early October, IntegraGen– a company that works on conversion of data from biological samples into genomic data and diagnostic tools for oncology– announced that Ocnotarget’s journal on the Expression Level of miR-31-3p with development-free survival in Metastatic Colorectal Cancer had been published. The article was explaining the relationship between of usefulness of anti-EGFR therapy and the standard of marker expression. Also featured were the remarks of the co-author and lead investigator of the research- John Primrose.
Primrose who is a Professor of surgery at the Southampton University expressed his delight in this achievement of being able to publish clinical data, which in the long term would help to customize therapeutic approaches and improve services that reached patients of metastatic colorectal cancer. Recent information had shown that colorectal cancer had become the third most common cancer and men and second in women. Every year, about 1.3 million new cases of the cancer are reported in the world. Of this, about 25% will be diagnosed with cancer at first diagnosis and 50% will develop it later after the diagnosis. The cancer had fast become the fourth cause of cancer-related deaths taking about 700,000 lives each year. The research would, therefore, help in saving so many lives.The miRpredX 31-3p kit that IntegraGen had of late announced its availability as a ready to use kit in testing FFPE tumors would also be helpful.
The miRpredX 31-3p was the first positive test for patients suffering from metastatic colorectal cancer. It would be used to predict the possible clinical benefit in the treatment of anti-EGFR therapy in comparison with anti-VEGF therapy in non-mutated RAS patients. IntegraGen is focused on providing researchers and tools that will see patient treatment improve. The company is based in Cambridge, USA.Oncotarget has become widely known since it was founded in 2010 as a peer-reviewed open access medical journal. It is published by the Impact Journals and covers research on the many aspects of oncology. The editors in chief of the journal are Andrei. V. Gudkov and Mikhail Blagosklonny of the Roswell Park Cancer Institute. They publish issues on a weekly basis, which can be printed for special demand. The journal looks to increase the impact of research through good and efficient reviews as well as to readily provide scientific research. Some of their other objectives include bridge the gap between specialties, create relationships between the fields of biomedical science as well as use clinical science to fight diseases.